- #134: Framework zur Unterstützung von Refundierungsentscheidungen zu digitalen Gesundheitsanwendungen (mHealth) und dessen (retrospektive) Anwendung an ausgewählten Beispielen
- #133: Effektivität von Musiktherapie bei Autismus, Demenz, Depression, Schlafstörung und Schizophrenie
- #132b: Lungenkarzinomscreening in Risikogruppen : Systematische Review(s) zu Kosten und Budgetfolgen (Teil 2)
- #132a: Lungenkarzinomscreening in Risikogruppen: Systematische Review(s) zu Wirksamkeit und Nutzen (Teil 1)
- #130: Molekulargenetische Diagnostik als Triage-Mechanismus in der Kardiologie am Beispiel der Familiären Hypercholesterinämie: Organisatorische und ethische Implikationen (Teil 1) sowie Ökonomische Auswirkungen (Teil 2)
- #129: Home-Treatment in der Kinder- und Jugendpsychiatrie: Eine Analyse zur Wirksamkeit und möglichen Implementierung in Österreich
- #128: Roboter und funktionelle Elektrostimulation zur Verbesserung der Funktionalität der oberen und unteren Extremitäten bei Patient*innen mit zentralen Insult-bedingten Lähmungen: eine systematische Übersichtsarbeit
- #127: Versorgungsforschung in der Onkologie Teil I: Versorgung am Lebensende (End-of-Life Care)
- #126: Versorgungsforschung in der Onkologie: Anti-PD-1/PD-L1-Therapie bei Patient*innen mit nicht-kleinzelligem Lungenkrebs (NSCLC) - Ergebnisse aus dem Versorgungsalltag
- #6b: ATMPs und Gentherapien in Entwicklung
- #5: Eltern-Kind-Pass Update 2020/21 - Screenings zu psychischer Gesundheit, Ernährung und sozialer Kompetenz: Empfehlungen aus evidenzbasierten Leitlinien
- #4: Protonen- und Kohlenstoffionen Protonen und Kohlenstoffionen Therapie. Update zu Indikationen
- #3: Update PET/PET-CT Evidenz zum Bedarf und zur Planung bei inkologischen Indikationen
- #2: Covid-19: HSS/ Horizon Scanning Living Document
- #1: Update 12 Monate Nachbeobachtung: Nusinersen bei Spinaler Muskelatrophie („late onset“) bei Kindern und Jugendlichen ≥ 6 Jahre
- DSD 123: Vaskuläre photodynamische Therapie mit Padeliporfin (Tookad® Lösung)
- DSD 122: Radiofrequenz-induzierte intravesikale Chemohyperthermie bei nicht-muskelinvasivem Blasenkrebs
- DSD 121: Perkutane transvaskuläre Implantation eines Stents zur Verengung des Koronarsinus
- DSD 120: Intrauterine ultraschallgesteuerte transzervikale Radiofrequenzablation
- DSD 119: Implantation eines telemedizinischen Pulmonalarterien-Drucksensors bei PatientInnen mit fortgeschrittener Herzinsuffizienz
- Update / DSD 106/1. Update 2020: Extrakorporale Zytokin Adsorption bei Sepsis und SIRS
- Update / DSD 97/2. Update 2020: Sondenloser Herzschrittmacher bei kardialen Arrhythmien
- #37/Update: Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer
- #36/Update: Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer
- #35/2. Update: Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)
- #34/Update: Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer
- #33/2. Update: Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis
- #32/Update: Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer
- #31/Update: Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma
- #30/Update: A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer
- #29/Update: Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)
- #28/2. Update: Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)
- #27/Update: Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)
- #26/Update: Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)
- #25/Update: Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)
- #24/Update: Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer
- #23/Update: Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)
- #22/Update: Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer
- #21/Update: Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)
- #20/Update: Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)
- #19/Update: Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)
- #18/Update: Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)
- #17/3. Update: Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)
- #16/2. Update: Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)
- #15/Update: Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)
- #14: Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL)
- #13/Update: Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC
- #12/Update: Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer
- #11: Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer
- #10: Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)
- #9: Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma
- #8/Update: Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen
- #7: Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation
- #6: Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)
- #5: Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)
- #4: Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC)
- #3: Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL
- #2: Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)
- #1: Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions